Trial Profile
A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide; Methylprednisolone; Methylprednisolone; Pomalidomide; Prednisone; Prednisone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biomira USA; Oncotherapeutics.
- 30 Oct 2023 Status changed from active, no longer recruiting to discontinued.
- 12 Aug 2020 Planned End Date changed from 1 Jul 2020 to 1 Sep 2020.
- 12 Aug 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Sep 2020.